Journal of General Virology · 1989 · 34 citations · 9 references
Life SciencesImmunologyInfectious DiseasesMolecular VirologyMonoclonal AntibodiesVirologyAntibody CharacterizationAntibody DiscoveryAntigenic VariationVaccine Antigen DiscoveryViral VaccinesYellow Fever17D VaccineAntigenic Variation In VirusesImmunofluorescence AssaysImmunofluorescence StainingMonoclonal Antibody SpecificityViral Antigen DetectionViral Antigen RecognitionYellow Fever Virus
Monoclonal antibodies (MAbs) against the Asibi wild-type strain of yellow fever (YF) virus were prepared and characterized. One of the MAbs (designated MAb 117) was shown, by cross-immunofluorescence tests with flaviviruses, to be specific for wildtype YF virus. This MAb was used in indirect immunofluorescence tests to identify wild-type antigenic variants in several different YF vaccine pools. Simultaneously, a vaccine-specific MAb prepared previously (MAb 864) was used to identify YF strain 17D vaccine type variants in the wild-type Asibi virus preparation. One variant, isolated by plaque purification from a 17D vaccine pool, possessed the wild-type epitope and was neurovirulent in infant mice whereas other variants, lacking the wild-type epitope but with vaccine-specific epitopes (identified by MAb 411), were avirulent in infant mice. Avirulent variants were able to infect mice and induce antibody. Virus-specific antigen was still detected in the brains of these mice 4 weeks after inoculation, suggesting that persistent infections were developing. These results to the potential risk of selection of wild-type variants in YF vaccine preparations. They also point to the potential risk of selection of wild-type variants in YF vaccine preparations and re-emphasize the need for modernization of techniques and more effective control measures to be taken during the production of YF vaccine.
9